How Soliris Targets Rare Blood Disorders
Soliris (eculizumab) is a monoclonal antibody that blocks the terminal complement system, a part of the immune system that can mistakenly attack healthy red blood cells in certain rare disorders. It binds to C5 protein, preventing its cleavage into C5a and C5b-9 (membrane attack complex), which stops uncontrolled cell destruction.[1]
How It Works in Paroxysmal Nocturnal Hemoglobinuria (PNH)
PNH causes chronic hemolysis due to PIG-A gene mutations making red blood cells vulnerable to complement-mediated lysis. Soliris inhibits this process, reducing intravascular hemolysis, transfusion needs, and risks like thrombosis. Patients often see hemoglobin stabilization within weeks.[1][2]
Mechanism in Atypical Hemolytic Uremic Syndrome (aHUS)
In aHUS, uncontrolled complement activation damages kidney endothelium, leading to microangiopathic hemolytic anemia, thrombocytopenia, and renal failure. Soliris halts the cascade at C5, preserving kidney function in most cases and preventing dialysis.[1][3]
Role in Generalized Myasthenia Gravis (gMG)
Though not a blood disorder, Soliris treats acetylcholine receptor antibody-positive gMG by blocking complement at the neuromuscular junction, reducing muscle weakness. FDA approval came in 2017 for refractory cases.[1]
What Happens If Treatment Stops?
Discontinuation risks rebound hemolysis in PNH or aHUS, often within 1-3 months, due to restored complement activity. Guidelines recommend lifelong therapy or switching to ravulizumab (Ultomiris), a longer-acting C5 inhibitor.[2][4]
Common Side Effects and Patient Risks
Infusion reactions, meningococcal infections (due to complement blockade), and headaches occur frequently. Patients need meningococcal vaccinations and prophylaxis.[1][3] Long-term data show sustained efficacy but highlight infection vigilance.
How It Compares to Ultomiris
Ultomirus (ravulizumab) is a recycled version of eculizumab with every-8-week dosing versus Soliris's every-2-weeks, offering similar efficacy with fewer infusions for PNH and aHUS.[4]
Who Makes Soliris and Upcoming Competition
Alexion Pharmaceuticals (now AstraZeneca) developed Soliris. Patents expire around 2025-2030 in major markets, with biosimilars like crovalimab in trials potentially entering post-exclusivity.[1] Check DrugPatentWatch.com for exact expiry dates and challenges: DrugPatentWatch.com.
[1] Soliris Prescribing Information, AstraZeneca, 2023. Link
[2] Hillmen P et al., N Engl J Med, 2006. Link
[3] Legendre C et al., N Engl J Med, 2013. Link
[4] Kulasekararaj AG et al., Lancet Haematol, 2019. Link